Table 3.
Association between patient characteristics and pathologic response defined by the classification of Japanese Breast Cancer Society
| Variables | QpCR | ||||
|---|---|---|---|---|---|
| Grade 3 | Grade 2b | Grade 0–2a | p value | ||
| SpCR | pCRinv | ||||
| All patients | 35 (9.9) | 37 (10.5) | 26 (7.4) | 255 (72.2) | |
| Study | |||||
| JBCRG-01 | 15 (8.1) | 16 (8.6) | 16 (8.6) | 139 (74.7) | 0.58 |
| JBCRG-02 | 6 (16.2) | 5 (13.5) | 2 (5.4) | 24 (64.9) | |
| JBCRG-03 | 14 (10.8) | 16 (12.3) | 8 (6.2) | 92 (70.8) | |
| Age | |||||
| <50 | 26 (11.3) | 19 (8.2) | 16 (6.9) | 170 (73.6) | 0.19 |
| ≥50 | 9 (7.4) | 18 (14.8) | 10 (8.2) | 85 (69.7) | |
| Tumor | |||||
| ≤3 cm | 20 (9.7) | 22 (10.6) | 13 (6.3) | 152 (73.4) | 0.82 |
| >3 cm | 15 (10.3) | 15 (10.3) | 13 (8.9) | 103 (70.6) | |
| Nuclear grade | |||||
| Grade 1 | 2 (2.9) | 3 (4.4) | 6 (8.7) | 58 (84.1) | 0.028 |
| Grade 2 | 9 (8.8) | 15 (14.7) | 7 (6.9) | 71 (69.6) | |
| Grade 3 | 13 (17.1) | 7 (9.2) | 5 (6.6) | 51 (67.1) | |
| Nodal status | |||||
| n0 | 29 (13.8) | 36 (17.1) | 18 (8.6) | 127 (60.5) | <0.001 |
| n+ | 6 (4.2) | 1 (0.7) | 8 (5.6) | 128 (89.5) | |
| Subtype | |||||
| Luminal | 6 (2.9) | 13 (6.3) | 13 (6.3) | 174 (84.5) | <0.001 |
| Luminal/Her2-positive | 5 (14.7) | 3 (8.8) | 6 (17.7) | 20 (58.8) | |
| Her2-positive | 6 (15.0) | 1 (27.5) | 4 (10.0) | 19 (47.5) | |
| Triple negative | 18 (24.7) | 10 (13.7) | 3 (4.1) | 42 (57.5) | |
| Clinical response after the first half of NAC | |||||
| CR, PR | 27 (12.6) | 24 (11.2) | 18 (8.4) | 145 (67.8) | 0.07 |
| SD, PD | 8 (5.8) | 13 (9.4) | 8 (5.8) | 110 (79.1) | |
| Clinical response before surgery | |||||
| CR, PR | 31 (11.9) | 31 (11.9) | 20 (7.7) | 179 (68.6) | 0.028 |
| SD, PD | 4 (4.5) | 5 (5.6) | 6 (6.7) | 74 (83.2) | |
CR complete response, NAC neoadjuvant chemotherapy, n+ node positive, PR partial response, SD stable disease, PD progressive disease